Perioperative Examination of Inflammatory Markers in Relation to Sentinel Lymph Node Biopsy in Patients With Melanoma; a Pilot Study

Aalborg University Hospital

Status: Completed

Conditions: Melanoma; Surgery

Treatments: Procedure: Blood samples

Study type: Observational

Funder types: Other

Identifiers

NCT05817149

2021-050

Details and patient eligibility

About

We want to test if an association between sentinel lymph node biopsy (SLBN) and a systemic inflammatory response can be made.

Full description

Sentinel lymph node biopsy (SLBN) is essential in staging melanoma and properly selecting patients for adjuvant immunotherapy. However, surgically induced inflammation can potentially aid in progression of remaining malignant cells and affect prognosis. The inflammatory marker neutrophil-to-lymphocyte ratio (NLR) is also a negative prognostic and predictive marker in serval malignancies, among melanoma. However, it is not yet established if SLNB induces a systemic inflammatory response.

Enrollment: 20 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult (>18 years of age)
• Diagnosed with invasive cutaneous melanoma
• Eligible for SLNB (Melanoma stage ≥ T1b)
• Obtained signed informed consent

Exclusion criteria

• Pregnancy

Trial design

20 participants in 1 patient group

Patients with melanoma

Description:

Patients with melanoma undergoing sentinel lymph node biopsy with perioperative blood samples.

Treatment:

Procedure: Blood samples